
|Articles|December 13, 2004
Heart drugs under study focus on impact on metabolism
Some help for battling the obesity epidemic may be arriving, according to continuing encouraging results for rimonabant (Acomplia, Sanofi-Aventis), not just in helping weight loss but also in improving metabolic risk factors. Other research at this year's American Heart Association 2004 Scientific Sessions, held recently in New Orleans, focused, as well, on metabolic effects of pharmacological agents.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
2
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
3
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
4


























































































































































